Trial Progress Update: Recent buzz on social media about SELLAS Life Sciences Group centers on the latest updates to their Phase 3 REGAL trial for GPS in Acute Myeloid Leukemia. Many users are highlighting the trial’s progress, with reports of nearing the final data readout as a key catalyst. The stock has seen significant gains, with some noting a premarket surge of over 15%.
Investor Optimism: Discussions also focus on the potential for positive trial outcomes and even speculation of a pharma acquisition. Some traders are pointing to high call volume and short squeeze potential as reasons for the momentum. The biotech sector’s tailwinds are frequently mentioned as a supportive factor for the stock’s rise.
Note: This discussion summary was generated from an AI condensation of post data.
SELLAS Life Sciences Group Insider Trading Activity
SELLAS Life Sciences Group insiders have traded $SLS stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SLS stock by insiders over the last 6 months:
- KATHERINE BACH KALIN purchased 63,400 shares for an estimated $100,806
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SELLAS Life Sciences Group Hedge Fund Activity
We have seen 50 institutional investors add shares of SELLAS Life Sciences Group stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANSON FUNDS MANAGEMENT LP added 5,757,938 shares (+2093.8%) to their portfolio in Q3 2025, for an estimated $9,270,280
- BLACKROCK, INC. added 1,096,613 shares (+23.9%) to their portfolio in Q3 2025, for an estimated $1,765,546
- MILLENNIUM MANAGEMENT LLC removed 812,523 shares (-72.1%) from their portfolio in Q3 2025, for an estimated $1,308,162
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 626,097 shares (-42.0%) from their portfolio in Q3 2025, for an estimated $1,008,016
- GOLDMAN SACHS GROUP INC removed 446,241 shares (-95.9%) from their portfolio in Q3 2025, for an estimated $718,448
- MARSHALL WACE, LLP removed 357,490 shares (-13.2%) from their portfolio in Q3 2025, for an estimated $575,558
- EVERHART FINANCIAL GROUP, INC. added 331,150 shares (+inf%) to their portfolio in Q3 2025, for an estimated $533,151
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SELLAS Life Sciences Group Analyst Ratings
Wall Street analysts have issued reports on $SLS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 07/16/2025
To track analyst ratings and price targets for SELLAS Life Sciences Group, check out Quiver Quantitative's $SLS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
